This article briefly analyzes recent Patent Trial and Appeal Board (PTAB) decisions on medical technology incorporating artificial intelligence (AI). Each decision involves reversal of a prior art rejection and contrasts with the other decisions on subject matter eligibility.
Recent Patent Trial and Appeal Board Approaches to Patent Claims on Medical Technology Implementing AI
Each decision involves reversal of a prior art rejection and contrasts with the other decisions on subject matter eligibility, revealing different PTAB approaches and results that can inform prosecution and appeal strategies.
By
Jim Soong
This premium content is locked for The Intellectual Property Strategist subscribers only
ENJOY UNLIMITED ACCESS TO THE SINGLE SOURCE OF OBJECTIVE LEGAL ANALYSIS, PRACTICAL INSIGHTS, AND NEWS IN The Intellectual Property Strategist
- Stay current on the latest information, rulings, regulations, and trends
- Includes practical, must-have information on copyrights, royalties, AI, and more
- Tap into expert guidance from top entertainment lawyers and experts
Already have an account? Sign In Now
For enterprise-wide or corporate access, please contact Customer Service at [email protected] or call 1-877-256-2473.
